Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CSIR launches...

    CSIR launches ayurvedic anti-diabetic drug BGR-34

    Written by savita thakur thakur Published On 2016-06-28T14:00:09+05:30  |  Updated On 28 Jun 2016 2:00 PM IST
    CSIR launches ayurvedic anti-diabetic drug BGR-34

    Bengaluru : The Council for Scientific and Industrial Research (CSIR) launched its ayurvedic anti-diabetic drug BGR-34.


    Aimed at managing type 2 diabetes, BGR-34 has been jointly developed by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), both located in Lucknow.


    "The modern diabetes drugs are known for side-effects and toxicity while BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs," said NBRIs' Senior Principal Scientist A.K.S. Rawat.


    NBRI and CIMAP scientists studied nearly 500 ancient herbs listed in ayurvedic texts to zero in on daruharidra (Berberis aristata), giloy (Tinospora cordifolia), vijaysar (Pterocarpus marsupium), gudmar (Gymnema sylvestre), majeeth (Rubia cordifoila) and methika (Trigonella foenum-graecum) to make the anti-diabetic formulation.


    Ayurvedic pharma compnay AIMIL Pharmaceuticals will commercially produce and distribute BGR- 34, which has been priced at Rs 5 and will be available widely across Karnataka and neighbouring states.


    "BGR-34 is a unique product that manages the lives of human suffering diabetics. The product passed several battery of tests and showed hypoglycaemic activity in experimental subjects," said AIMIL Pharmaceuticals vice president Anil Kumar Sharma.

    A K S RawatAIMIL PharmaAnil Kumar Sharmaanti-diabetic drugayurvedic anti-diabetic drugAyurvedic pharmaBGR-34Central Institute for Medicinal and Aromatic PlantsCIMAPCouncil for Scientific and Industrial ResearchCSIRNational Botanical Research InstituteNBRItype-2 diabetes
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok